LIGHTBIO
LIVE

Serial Number

79279617

Owner

LightBio Limited

Attorney

Rebecca Liebowitz

Filing Date

Aug 28, 2019

Add to watchlist:

No watchlists yet
View on USPTO

LIGHTBIO Trademark

Serial Number: 79279617 • Registration: 6375045

LIGHTBIO is a trademark filed by LightBio Limited on August 28, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

LightBio Limited (4 trademarks)

Morelands And Riverdale Buildings,

Entity Type: 99

Trademark Details

Filing Date

August 28, 2019

Registration Date

June 8, 2021

Published for Opposition

March 23, 2021

Goods & Services

Chemical treatment of DNA to form DNA extracts; custom manufacture of therapeutic DNA by the manipulation of DNA into DNA extracts or cassettes

Scientific apparatus and instruments, namely, apparatus for amplifying DNA, namely, reactors and bioreactors; apparatus for manufacturing DNA, namely, reactors and bioreactors; apparatus for processing DNA, namely, reactors and bioreactors; electronic components, namely, nucleic acid analogues in the nature of electric and power wires, semi-conductors, transistors, rectifiers, diodes, light emitting diodes and energy storage systems in the nature of devices for energy storage, namely, batteries, fuel cells configured for energy storage, and electrochemical devices configured for energy storage, namely, electrolysers; electric and power wires comprised of nucleic acid composites (NACs) semi-conductors, transistors, rectifiers, diodes, light emitting diodes and energy storage systems in the nature of devices for energy storage, namely, batteries, fuel cells configured for energy storage, and electrochemical devices configured for energy storage, namely, electrolysers, each comprised of nucleic acid composites (NACs); labeling, imaging and sensing apparatus comprising of nucleic acid composites (NACs) for laboratory and research use; smart materials in the nature of DNA chips, DNA microarrays, comprised of nucleic acid composites; two-dimensional and three-dimensional nucleic acid composites (NACs) in the nature of DNA chips, DNA microarrays for creating nanostructures and scaffolds for use in electronic components and materials, namely, electrical conductors; parts and fittings for all the aforesaid technology and parts and fittings for all the aforesaid goods, namely, electrical cables, display screens, transmitters

Vaccines; DNA based vaccines; DNA extracts, namely, nucleic acid sequences and chemical reagents for medical use; therapeutic DNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labeling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffolds

Chemical preparations, enzymes and DNA for the preparation of nucleic acid for scientific research; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific and research use; DNA extracts for use in scientific research in the field of agri-biotechnology and nanotechnology; nucleic acids comprising natural and unnatural nucleotides for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; nucleic acid analogues with organic and inorganic chemicals for laboratory use in labelling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for laboratory use in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for laboratory use in creating nanostructures and scaffolds; Nucleic acids comprising natural and unnatural nucleotides for laboratory use; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for laboratory use; composites of nucleic acids or nucleic acid analogues with organic and NAC inorganic chemicals for laboratory use; all the aforesaid goods for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing

Scientific and technological services and research and design relating thereto, namely, chemical and biological analysis and research services; DNA analysis services for scientific research purposes; scientific research and development into the creation of DNA extracts; scientific research, analysis, design and development relating to DNA based drugs and therapies; scientific research and development in the fields of gene therapy, genetic diagnostics, agri-biotechnology and nanotechnology, all in the field of gene therapy; consultancy relating to the aforesaid services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 24, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 28, 2021 FICS
FINAL DISPOSITION PROCESSED
Sep 28, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 8, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 8, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 23, 2021 NPUB
PUBLISHED FOR OPPOSITION
Mar 23, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Mar 21, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 3, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 3, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 3, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 16, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 16, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 16, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 16, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 16, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 11, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 11, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 11, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 7, 2021 GNFN
FINAL REFUSAL E-MAILED
Jan 7, 2021 GNFR
FINAL REFUSAL WRITTEN
Jan 7, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 17, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 17, 2020 CRFA
ASSIGNED TO LIE
Dec 15, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 21, 2020 TROA
REFUSAL PROCESSED BY IB
Apr 10, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 25, 2020 RFCS
REFUSAL PROCESSED BY MPU
Mar 25, 2020 RFRR
APPLICATION FILING RECEIPT MAILED
Mar 6, 2020 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 4, 2020 RFCR
NON-FINAL ACTION WRITTEN
Mar 3, 2020 CNRT
ASSIGNED TO EXAMINER
Mar 2, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 2, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 27, 2020 REPR